GlassScriptPhysician profile
Bryant D Uy
NPI 1346509213
$19,250.55
in general payments reported to CMS, 2019-2025
40 companies · $4,425 in 2025
The $4,425 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,115 · 2022: $3,558 · 2023: $4,244 · 2024: $3,910 · 2025: $4,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,409.38 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,756.60 | 2021-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $3,247.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,937.04 | 2021-2025 | |
| Janssen Biotech, INC. | $1,369.19 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,178.87 | 2021-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $1,107.53 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $1,100.96 | 2021-2025 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $1,027.97 | 2021-2023 | Krystexxa |
| Radius Health, INC. | $966.75 | 2021-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $442.05 | 2021-2025 | Saphnelo, Fasenra |
| Pfizer INC. | $431.64 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $279.37 | 2021-2025 | Strensiq, Ultomiris |
| Sobi, INC | $227.42 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $204.70 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $187.58 | 2021-2024 | Acthar |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $184.07 | 2022-2024 | Purified Cortrophin Gel |
| Argenx US, INC. | $145.53 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Fresenius Kabi USA, LLC | $120.85 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Kiniksa Pharmaceuticals, LTD. | $107.12 | 2021-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $105.12 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $98.39 | 2022-2024 | Amvuttra |
| Fidia Pharma USA INC. | $93.99 | 2021-2025 | Triluron, Hymovis |
| Genentech USA, INC. | $93.24 | 2023-2024 | Actemra, Ocrevus |
| Alvogen INC | $85.66 | 2023-2024 | Teriparatide |
| Daiichi Sankyo INC. | $84.46 | 2021 | |
| Depuy Synthes Sales INC. | $78.94 | 2021-2024 | Monovisc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.51 | 2023-2024 | Cyltezo |
| Octapharma USA, INC. | $74.83 | 2025 | Panzyga, Octagam Immune Globulin (Human) |
| E.R. Squibb & Sons, L.L.C. | $73.17 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $63.99 | 2021-2022 | |
| Pacira Therapeutics, INC. | $62.09 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.28 | 2023-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $33.12 | 2024 | Dupixent |
| Organon LLC | $31.71 | 2023 | Hadlima |
| Zimmer Biomet Holdings, INC. | $29.56 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Csl Behring | $28.82 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $21.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.09 | 2023 | Gammagard |
| Avanos Medical | $18.02 | 2024 | Trivisc Sodium Hyaluronate |
| Ferring Pharmaceuticals INC. | $17.03 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Uy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.